Plasma lipids and lipoprotein-cholesterol distribution in nephrotic syndrome patients during short term high dose steroid treatment.
Plasma lipids and lipoprotein-cholesterol profiles were studies in 11 consecutive patients (eight females and three males) with the nephrotic syndrome (NS) during a short term treatment with high dose prednisolone. A significant fall from the high mean pre-treatment levels of total cholesterol and LDL-cholesterol was demonstrated at four, eight and 12 weeks of treatment (p < 0.005) while the fall in the mean triglyceride level only became significant at eight weeks (p < 0.01). The mean HDL-cholesterol level did not change significantly throughout, although there was a significant rise in the mean HDL-cholesterol total cholesterol ratio at four weeks (p = 0.01) and at both eight and 12 weeks (p < 0.005). The study has demonstrated a significant improvement in the lipids and lipoprotein-cholesterol profile of patients with the nephrotic syndrome during a shortterm high dose steroid treatment.
Arije
A
A
Department of Medicine, Faculty of Health Sciences, University of Ilorin, Kwara State, Nigeria.
Erasmus
R T
RT
Anjorin
S A
SA
D000293:Adolescent; D000328:Adult; D000368:Aged; D001706:Biopsy; D002648:Child; D002784:Cholesterol / Q000097:blood*; D008076:Cholesterol, HDL / Q000097:blood* / Q000187:drug effects; D008078:Cholesterol, LDL / Q000097:blood* / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology; D011239:Prednisolone / Q000494:pharmacology / Q000627:therapeutic use*; D012709:Serum Albumin / Q000032:analysis / Q000187:drug effects; D013997:Time Factors; D014280:Triglycerides / Q000097:blood*
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D012709:Serum Albumin; D014280:Triglycerides; D002784:Cholesterol; D011239:Prednisolone